Table 1. General tumour growth parameters for the different groups.
Cell Number | FaDu | LN229 | ||||||
---|---|---|---|---|---|---|---|---|
n | Take rate | Allocation rate | Allocation time / d (± sem) |
n | Take rate | Allocation rate | Allocation time / d (± sem) |
|
PBS | ||||||||
1*106 | 10 | 0.70 | 0.57 | 18.8 ± 2.8 | ||||
1*105 | 19 | 0.84 | 0.69 | 106.2 ± 9.7 | ||||
9.7 mg/ml Matrigel | ||||||||
1*106 | 16 | 1.0 | 0.69 | 7.4 ± 1.5 | ||||
1*105 | 16 | 1.0 | 0.69 | 13.3 ± 1.7 | 19 | 0.95 | 0.50 | 23.6 ± 2.0 |
1*104 | 16 | 0.81 | 0.62 | 19.4 ± 2.0 | 19 | 0.89 | 0.75 | 28.5 ± 2.7 |
1*103 | 17 | 0.82 | 0.36 | 26.0 ± 3.0 | 13§ | 0.92 | 0.36 | 45.8 ± 3.9 |
1*102 | 18 | 0.39 | 0.0 | --- | ||||
4.85 mg/ml Matrigel (MG:PBS 1:1) | ||||||||
1*106 | 15 | 0.93 | 0.21 | 13.7 ± 4.6 | ||||
1*105 | 16 | 0.94 | 0.53 | 18.9 ± 1.1 | ||||
1*104 | 16 | 0.94 | 0.53 | 24.9 ± 2.3 | ||||
1*103 | 16 | 0.56 | 0.44 | 27.8 ± 1.7 |
§ During injection of the 2nd cohort of LN229 premature gelatinisation of MG causes a stop of injection in that particular group; the remaining animals of that group were allotted to the other groups.